Tango Therapeutics, Inc. (TNGX) Tops Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. FND
10. GILD

Go back to Tango Therapeutics, Inc. (TNGX) Tops Q4 EPS by 3c

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

March 27, 2023 7:00 AM EDT

Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor

Adam Crystal, M.D., Ph.D. appointed President of Research and Development

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.

2022 was an important year for Tango, as we made critical strides in advancing our programs. We advanced our... More